RHOB and neoplasm: Tipifarnib is a farnesyltransferase inhibitor with the potential of increasing radiosensitivity by blocking activity of the RAS- and RhoB-oncogen pathways while also reducing tumor hypoxia by controlling MMP2 expression [30, 31].